Colossal Biosciences Faces Ethical Scrutiny Over Mammoth De-Extinction Goals

Colossal Biosciences, the Dallas-based biotechnology firm co-founded by serial entrepreneur Ben Lamm and Harvard geneticist George Church, has become the epicenter of a global debate over the limits of synthetic biology. By attempting to 'de-extinct' the woolly mammoth, the company is not merely performing a scientific stunt; it is pioneering a new industry of functional restoration that seeks to use CRISPR gene-editing technology to reverse the loss of biodiversity. However, as the company moves closer to its 2028 target for the first mammoth-elephant hybrid calf, the ethical and ecological controversy surrounding the project has intensified, highlighting a fundamental rift between technological optimism and traditional conservation philosophy.

The core of Colossal’s technical strategy lies in the Asian elephant, which shares 99.6% of its DNA with the extinct woolly mammoth. Using CRISPR-Cas9, Colossal’s scientists are identifying and inserting specific mammoth genes—those responsible for thick hair, subcutaneous fat, and cold-tolerant hemoglobin—into the Asian elephant genome. The goal is not a 100% genetic clone, but a 'mammoth proxy' that can survive in the Arctic tundra. This approach represents a significant shift in biotech, moving from therapeutic applications for humans to the large-scale modification of entire species for environmental engineering.

“

The core of Colossal’s technical strategy lies in the Asian elephant, which shares 99.6% of its DNA with the extinct woolly mammoth.

From an ecological perspective, Colossal argues that reintroducing mammoth-like creatures to the Arctic could help mitigate climate change. The theory, often called 'Pleistocene Rewilding,' suggests that large herbivores could help maintain the grasslands of the tundra, preventing the melting of permafrost and the subsequent release of massive amounts of carbon dioxide and methane. Critics, however, remain skeptical of these claims. They argue that the Arctic ecosystem has changed significantly in the 4,000 years since mammoths went extinct, and introducing a synthetic hybrid could have unpredictable, potentially disastrous consequences for existing flora and fauna. Furthermore, there are deep concerns regarding the welfare of the surrogate Asian elephants that would be required to carry these hybrid calves to term.

The controversy also extends to the financial and moral priorities of the biotech sector. With over $225 million in venture capital funding from a diverse group of investors—including Peter Thiel, Paris Hilton, and Breyer Capital—Colossal is one of the best-funded startups in the de-extinction space. Conservationists argue that these hundreds of millions of dollars would be better spent protecting species that are currently on the brink of extinction due to habitat loss and poaching. There is a fear of 'moral hazard': if society believes that extinction is reversible through technology, the urgency to preserve existing biodiversity may diminish.